Biosimilar Development News

  1. Magellan Rx Management Biosimilar Program Shifts Infliximab Utilization By 86% In First Year, Resulting In 34% Drug Cost Savings
    4/16/2019

    Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc., released new data recently showcasing results from its medical pharmacy program focused on biosimilar management.

  2. Surge Of Indian Biosimilars Market Forecast In 2019
    4/16/2019

    New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production.

  3. Biosimilars Market Size To Reach $26.7B By 2024: P&S Intelligence
    4/15/2019

    According to the market research report published by P&S Intelligence, biosimilars market is expected to generate $26.7 billion revenue by 2024, advancing at a CAGR of 29.6% during the forecast period. The market is majorly driven by rising prevalence of chronic diseases, increasing investment in research and development (R&D) activities by biopharmaceutical companies, extensive pipeline of biosimilars, growing geriatric population, and inexpensive nature of biosimilars as compared to reference drugs.

  4. Biosimilar Pipeline Analysis Market Application With Its Leading Manufacturers Biocon, Pfizer, F. Hoffmann-La Roche, Amgen, AstraZeneca, Novartis AG, And Merck
    4/11/2019

    Biosimilar is a type of biological product that is almost identical to the original product, which has undergone patent expiration. Development and validation of biosimilars are an important part of the overall production process.

  5. Teva Canada Announces The Approval Of TRUXIMA™, The First Biosimilar To RITUXAN® In Canada For The Treatment Of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia And Rheumatoid Arthritis
    4/10/2019

    Teva Canada Innovation, G.P.-.S.E.N.C. announces that Health Canada has granted a notice of compliance (NOC)for TRUXIMA™ (rituximab), the first biosimilar to RITUXAN®2 (rituximab) in Canada for the treatment of adult patients in: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA).

  6. PCMA: Greater Competition On Insulin Products Key To Reducing Prices
    4/10/2019

    The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today's hearing on the important issue of rising insulin prices.

  7. Generium Launches First Biosimilar Of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
    4/9/2019

    Selexis SA and Generium JSC recently announced that a fifth Selexis SUREtechnology Platform-generated biological product has been approved for marketing.

  8. AAM Statement On House Energy & Commerce Passage Of The CREATES Act
    4/4/2019

    The Association for Accessible Medicines welcomes recently’s unanimous 51-0 passage of the CREATES Act by the House Energy and Commerce Committee.

  9. Fresenius Kabi Receives European Commission Approval For Adalimumab Biosimilar IDACIO
    4/3/2019

    Fresenius Kabi, a global healthcare company that specializes in lifesaving medicines and technologies, announced recently that the European Commission (EC) granted marketing authorization for IDACIO, an adalimumab biosimilar, for all indications of the reference medicine.

  10. Sandoz Resubmits Biosimilar Pegfilgrastim Application To US FDA
    4/3/2019

    Sandoz, a Novartis division and a global leader in biosimilars, today announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and Drug Administration (FDA) to address an FDA complete response letter received in June 2016.